Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 12.05.2023 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | s as a result of the reassessment described under Item 4.02 above. These forward-looking statements are subject to the s |
Stammdaten
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Unternehmen & Branche
| Name | CalciMedica, Inc. |
|---|---|
| Ticker | CALC |
| CIK | 0001534133 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 9,3 Mio. USD |
| Beta | 1,09 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -29,562,000 | -1.97 | 13,591,000 | -6,641,000 | |
| 2025-09-30 | 10-Q | -7,804,000 | -0.52 | 14,913,000 | -268,000 | |
| 2025-06-30 | 10-Q | -5,956,000 | -0.40 | 19,080,000 | 6,103,000 | |
| 2025-03-31 | 10-Q | -5,042,000 | -0.36 | 25,347,000 | 10,888,000 | |
| 2024-12-31 | 10-K | -13,700,000 | -1.22 | 19,794,000 | 14,410,000 | |
| 2024-09-30 | 10-Q | -5,618,000 | -0.50 | 16,212,000 | 9,030,000 | |
| 2024-06-30 | 10-Q | -3,954,000 | -0.36 | 21,052,000 | 13,838,000 | |
| 2024-03-31 | 10-Q | 130,000 | 0.01 | 27,134,000 | 17,247,000 | |
| 2023-12-31 | 10-K | -34,357,000 | -7.66 | 12,185,000 | 8,157,000 | |
| 2023-09-30 | 10-Q | -4,619,000 | -0.82 | 15,845,000 | 12,159,000 | |
| 2023-06-30 | 10-Q | -6,304,000 | -1.11 | 20,245,000 | 16,221,000 | |
| 2023-03-31 | 10-Q | -19,288,000 | -23.43 | 34,669,000 | 22,019,000 | |
| 2022-12-31 | 10-K | -7,824,000 | -111.16 | 3,349,000 | -71,304,000 | |
| 2022-09-30 | 10-Q | -2,581,000 | -31.04 | 45,361,000 | -71,789,000 | |
| 2022-06-30 | 10-Q | -3,030,000 | -36.55 | 54,022,000 | -69,973,000 | |
| 2022-03-31 | 10-Q | -3,630,000 | -46.13 | 60,586,000 | -67,281,000 | |
| 2021-12-31 | 10-K | -35,821,000 | -1.69 | 69,088,000 | -63,987,000 | |
| 2021-09-30 | 10-Q | -7,989,000 | -0.38 | 76,638,000 | 72,136,000 | |
| 2021-06-30 | 10-Q | -7,708,000 | -0.36 | 82,821,000 | 78,667,000 | |
| 2021-03-31 | 10-Q | -11,449,000 | 90,852,000 | 84,562,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-09-18 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 2,500 | 3.07 | 7,675.00 | +90,4% | |
| 2025-09-15 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 3,400 | 2.68 | 9,104.86 | +107,3% | |
| 2025-09-12 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 5,000 | 3.12 | 15,600.00 | +183,8% | |
| 2025-09-09 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 2,343 | 3.15 | 7,377.64 | +86,9% | |
| 2025-08-29 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 800 | 2.74 | 2,192.00 | +25,8% | |
| 2025-08-28 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 9,200 | 2.86 | 26,339.60 | +310,4% | |
| 2025-08-21 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 3,508 | 2.79 | 9,797.14 | +115,4% | |
| 2025-08-20 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 2,000 | 2.72 | 5,440.00 | +64,1% | |
| 2025-08-19 | Hebbar Sudarshan | Officer, Chief Medical Officer | Open Market Purchase | 9,563 | 2.82 | 26,961.92 | +317,7% | |
| 2025-08-19 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 1,000 | 2.79 | 2,790.00 | +32,9% | |
| 2025-08-15 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 5,076 | 2.90 | 14,708.73 | +173,3% | |
| 2025-08-15 | Hebbar Sudarshan | Officer, Chief Medical Officer | Open Market Purchase | 4,392 | 2.79 | 12,266.86 | +144,6% | |
| 2025-08-14 | Hebbar Sudarshan | Officer, Chief Medical Officer | Open Market Purchase | 1,584 | 2.59 | 4,094.64 | +48,3% | |
| 2025-07-28 | Stauderman Kenneth A. | Officer, Chief Scientific Officer | Open Market Purchase | 1,000 | 3.96 | 3,960.00 | +46,7% | |
| 2025-07-25 | Stauderman Kenneth A. | Officer, Chief Scientific Officer | Open Market Sale | -1,000 | 3.65 | -3,650.00 | -43,0% | |
| 2025-07-22 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 1,500 | 3.78 | 5,662.50 | +66,7% | |
| 2025-07-21 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 1,500 | 3.37 | 5,055.00 | +59,6% | |
| 2025-07-21 | Leheny A. Rachel | Director, Officer, 10% Owner, CHIEF EXECUTIVE OFFICER | Open Market Purchase | 1,000 | 3.40 | 3,400.00 | +40,1% | |
| 2025-07-18 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 2,000 | 2.88 | 5,760.00 | +67,9% | |
| 2025-07-18 | WILSON ROBERT N | Director | Open Market Purchase | 4,500 | 2.87 | 12,915.00 | +152,2% | |
| 2025-07-14 | Leheny A. Rachel | Director, Officer, 10% Owner, CHIEF EXECUTIVE OFFICER | Open Market Purchase | 2,500 | 2.47 | 6,175.00 | +72,8% | |
| 2025-07-14 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 6,500 | 2.43 | 15,809.95 | +186,3% | |
| 2025-07-09 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 5,000 | 1.60 | 8,023.50 | +94,5% | |
| 2025-07-01 | Stauderman Kenneth A. | Officer, Chief Scientific Officer | Open Market Purchase | 1,000 | 1.85 | 1,850.00 | +21,8% | |
| 2025-06-26 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 4,500 | 1.44 | 6,482.70 | +76,4% | |
| 2025-06-26 | Bardin Stephen | Officer, Chief Financial Officer | Open Market Purchase | 2,000 | 1.50 | 3,005.00 | +35,4% | |
| 2025-06-11 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 5,000 | 1.85 | 9,250.00 | +109,0% | |
| 2025-06-06 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 5,000 | 1.78 | 8,875.00 | +104,6% | |
| 2025-06-05 | Roberts Eric W | Director, Officer, 10% Owner, CHIEF BUSINESS OFFICER | Open Market Purchase | 5,100 | 1.70 | 8,670.00 | +102,2% | |
| 2025-05-30 | Bardin Stephen | Officer, Chief Financial Officer | Open Market Purchase | 1,000 | 1.69 | 1,690.00 | +19,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.